These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 31754402)

  • 1. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.
    Garbuzenko OB; Kuzmov A; Taratula O; Pine SR; Minko T
    Theranostics; 2019; 9(26):8362-8376. PubMed ID: 31754402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.
    Taratula O; Kuzmov A; Shah M; Garbuzenko OB; Minko T
    J Control Release; 2013 Nov; 171(3):349-57. PubMed ID: 23648833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
    Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
    Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-delivery of gefitinib and hematoporphyrin by aptamer-modified fluorinated dendrimer for hypoxia alleviation and enhanced synergistic chemo-photodynamic therapy of NSCLC.
    Zhu F; Xu L; Li X; Li Z; Wang J; Chen H; Li X; Gao Y
    Eur J Pharm Sci; 2021 Dec; 167():106004. PubMed ID: 34520834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells.
    Zhao XM; Pan SY; Huang QL; Lu YN; Wu XH; Chang JH; Liu ZB; Cai XW; Liu Q; Wang JL; Fu XL
    Oncotarget; 2016 Aug; 7(31):49384-49396. PubMed ID: 27283902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
    BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer.
    Mao J; Ma L; Shen Y; Zhu K; Zhang R; Xi W; Ruan Z; Luo C; Chen Z; Xi X; Chen S
    Cell Death Dis; 2018 Sep; 9(10):963. PubMed ID: 30237564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
    Tsai CM; Chen JT; Chiu CH; Lai CL; Hsiao SY; Chang KT
    Lung Cancer; 2013 Nov; 82(2):305-12. PubMed ID: 24055492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-delivery of PD-L1- and EGFR-targeting siRNAs by synthetic PEG
    Man RCH; Qiu Y; Leung SWS; Fruhwirth GO; Lam JKW
    Eur J Pharm Biopharm; 2024 Feb; 195():114177. PubMed ID: 38185193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.
    Cortes-Funes H; Gomez C; Rosell R; Valero P; Garcia-Giron C; Velasco A; Izquierdo A; Diz P; Camps C; Castellanos D; Alberola V; Cardenal F; Gonzalez-Larriba JL; Vieitez JM; Maeztu I; Sanchez JJ; Queralt C; Mayo C; Mendez P; Moran T; Taron M
    Ann Oncol; 2005 Jul; 16(7):1081-6. PubMed ID: 15851406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations.
    Majumder J; Minko T
    Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.